Piperacillin Sodium for Injection

Piperacillin is a semi-synthetic penicillin antibiotic with a broad-spectrum antibacterial effect. Piperacillin has good antibacterial effects on Enterobacteriaceae such as Escherichia coli, Proteus, Serratia, Klebsiella, Enterobacter, Citrobacter, Salmonella and Shigella, as well as other Gram-negative bacteria such as Pseudomonas aeruginosa, Acinetobacter, Haemophilus influenzae and Neisseria. This product also has certain antibacterial activity against Enterococci, Group A and Group B hemolytic streptococci, Streptococcus pneumoniae and Staphylococci that do not produce penicillinase. Many anaerobic bacteria, including Bacteroides fragilis and Clostridium, are also sensitive to piperacillin. The mechanism of action of piperacillin is to exert a bactericidal effect by inhibiting bacterial cell wall synthesis.

The main component of this product is piperacillin sodium, and its chemical name is (2S,5R,6R)-3.3-dimethyl-6-[(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)phenylacetylamino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid sodium salt. Molecular formula: C23H26N5NaO7S Molecular weight: 539.54

This product is white or off-white powder or loose lumps, odorless, and highly hygroscopic.

It is suitable for sepsis caused by sensitive Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter, upper urinary tract and complicated urinary tract infections, respiratory tract infections, biliary tract infections, abdominal infections, pelvic infections, and skin and soft tissue infections. Piperacillin combined with aminoglycosides can also be used for infections in immunocompromised patients with neutropenia.

This product can be used for intravenous drip and intravenous injection. For moderate infection in adults, 8g a day, divided into 2 intravenous drips; for severe infection, 3-4g once, intravenous drip or injection every 4-6 hours. The total daily dose should not exceed 24g. The dose for infants and children under 12 years old is 100-200mg/kg per day according to body weight. For newborns weighing less than 2kg, 50mg/kg is given by intravenous drip every 12 hours in the first week after birth; 50mg/kg is given once every 8 hours from the second week onwards. For newborns weighing more than 2kg, 50mg/kg is given by intravenous drip every 8 hours in the first week after birth; 50mg/kg is given every 6 hours for those weighing more than 1 week.

1. Allergic reactions: Allergic reactions to penicillins are common, including urticaria and other types of rashes, leukopenia, interstitial nephritis, asthma attacks and serum sickness reactions. In severe cases, anaphylactic shock is occasionally seen. Once anaphylactic shock occurs, it must be rescued on the spot, and treatment measures such as keeping the airway open, oxygen inhalation, and adrenaline and glucocorticoids must be given. 2. Local symptoms: pain at the local injection site, thrombophlebitis, etc. 3. Gastrointestinal symptoms: diarrhea, loose stools, nausea, vomiting, etc.; pseudomembranous colitis is rare. 4. Cholestatic jaundice may occur in some patients. 5. Central nervous system symptoms: headache, dizziness, fatigue, etc. 6. When a large dose is used in patients with impaired renal function, penicillin encephalopathy occurs due to increased cerebrospinal fluid concentration, so the dose should be adjusted according to renal function at this time. 7. Others: Candida superinfection, bleeding, etc.

It is contraindicated in patients with a history of allergy to penicillins or a positive penicillin skin test.

1. In vitro, this product has a synergistic antibacterial effect against Pseudomonas aeruginosa and some Enterobacteriaceae when used in combination with aminoglycosides (amikacin, gentamicin or tobramycin). 2. This product is used in combination with cefoxitin, because the latter can induce bacteria to produce β-lactamase and has an antagonistic effect on Pseudomonas aeruginosa, Serratia, Proteus and Enterobacter. 3. When used in combination with anticoagulants such as heparin, coumarin, indandione and non-steroidal anti-inflammatory analgesics, the risk of bleeding may be increased, and when used in combination with suppository solvents, severe bleeding may occur. 4. This product and aminoglycoside antibiotics cannot be dripped in the same bottle, otherwise the antibacterial activity of both will be weakened.

Keep tightly closed in a cool, dark and dry place.

1.0g (calculated as C23H27N5O7S)

North China Pharmaceutical Company.Ltd

• Founded in:

  1992-12-20

• Address:

  No. 388, Heping East Road, Shijiazhuang City

• Tax NO.:

  91130100104397700P

• Registered Funds:

  1,715,730,370 yuan

• Website:

  Log in to view

• Email:

  Log in to view